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Buoyed by a burgeoning medical culture of “appropriate use”
and rising doctor awareness of the financial ruin that threatens
many patients who navigate expensive treatments in pursuit of
better health, medical specialist societies have grown
increasingly vocal about integrating economic value in their
clinical guidelines.1 These encouraging developments are,
however, threatened by a worsening decline in the
generalisability of randomised controlled trials, a concern
supported by widening differences between the characteristics
of patients enrolled in trials and those of the populations targeted
for intervention outside trials.2-4
Randomised clinical trials are the highest level of evidence for
comparative health effectiveness, but they also provide the
highest evidentiary standard for comparative cost and cost
effectiveness. Although many cost effectiveness analyses are
performed with sophisticated mathematical models, we believe
that economic evaluations performed alongside randomised
trials with individual participant data will have an increasingly
important role (figure⇓). However, because patients in
randomised trials often differ substantially from patients in the
target population the generalisability of within trial cost
effectiveness can be significantly threatened by the heterogeneity
of treatment effects.3 By interacting with differences in
generalisability and thereby distorting cost effectiveness,
treatment heterogeneity is a challenge to the integration of
economic analyses in specialist society guidelines and health
policy.
We propose that trialists enrolling populations that differ
substantially from target populations should share individual
participant economic data so that researchers can determine
how these differences affect cost effectiveness.5 The use of
economic outcomes in guideline development by specialist
societies is a reasonable and encouraging step towards providing
patients and doctors with transparent information about value.
Addressing the pitfalls in the process promises to improve the
societies’ decisionmaking and patient care. Public dissemination
of study data will greatly help.6
We thank Dr Richard Frank, whose contributions to a National Heart,
Lung, and Blood Institute (NHLBI) webinar entitled “Integrating economic
analysis into NIH funded research” helped to inform this work.
Competing interests: None declared.
1 Schwartz JA, Pearson SD. Cost consideration in the clinical guidance documents of
physician specialty societies in the United States. JAMA Intern Med 2013;173:1091-7.
2 Sardar MR, Badri M, Prince CT, et al. Underrepresentation of women, elderly patients,
and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA
Intern Med 2014;174:1868-70.
3 Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: Race-, sex-,
and age-based disparities. JAMA 2004;291:2720-6.
4 Udell JA, Wang TY, Li S, et al. Clinical trial participation after myocardial infarction in a
national cardiovascular data registry. JAMA 2014;312:841-3.
5 Cole SR, Stuart EA. Generalizing evidence from randomized clinical trials to target
populations: The ACTG 320 trial. Am J Epidemiol 2010;172:107-15.
6 Loder E, Groves T. The BMJ requires data sharing on request for all trials. BMJ
2015;350:h2373. (7 May.)
Cite this as: BMJ 2015;350:h3091
© BMJ Publishing Group Ltd 2015
joseph.ladapo@nyumc.org
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe




Numbers of publications of randomised controlled trials in PubMed that include an economic evaluation. Search terms
included the medical subject headings cost-benefit analysis and randomised controlled trial
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;350:h3091 doi: 10.1136/bmj.h3091 (Published 8 June 2015) Page 2 of 2
LETTERS
